AusperBio's AHB-137 Presentation Set to Make Waves at AASLD
Exciting Developments from AusperBio at AASLD 2024
AusperBio Therapeutic, Inc. and Ausper Biopharma Co., Ltd. (together AusperBio) are making headlines with their innovative clinical-stage work. This promising biotechnology company is set to present groundbreaking clinical data regarding their lead candidate, AHB-137. This antisense oligonucleotide (ASO) therapeutic aims to provide a functional cure for chronic hepatitis B.
Key Details on the Upcoming Presentation
The much-anticipated presentation will be delivered at the renowned Liver Meeting, organized by the American Association for the Study of Liver Diseases (AASLD). This significant event is scheduled for mid-November and will bring together experts in the field to discuss advancements in liver disease treatment.
AHB-137’s oral presentation will focus on new findings that underline its potential impact on treatment outcomes for patients suffering from chronic hepatitis B. The details of the presentation are as follows:
Presentation Information
Title: HBsAg loss and seroconversion in HBeAg-negative chronic hepatitis B subjects on NA therapy after AHB-137 treatment: preliminary data from an ongoing multicenter, randomized, open-label phase IIa study.
Session: Late Breaking Abstract Parallel Session 2
Session Time: November 18, 2024, from 5:00 PM to 6:30 PM PDT
Presentation Time: November 18, 2024, from 6:00 PM to 6:15 PM PDT
Authors: The research team, including Yanhua Ding and others, will present the findings which are pivotal for understanding the therapeutic efficacy and potential of AHB-137.
Understanding AHB-137 and Its Mechanisms
AHB-137 is an innovative unconjugated antisense oligonucleotide developed through AusperBio's proprietary Med-Oligo™ ASO technology platform. This specialized platform is designed to treat chronic hepatitis B with an aim to achieve a functional cure. The company has showcased AHB-137's impressive preclinical and Phase 1 clinical data, drawing interest from the scientific community.
The therapy exemplifies a dual-mechanism action that targets the virus in unique ways, setting it apart from other treatments currently available. Presently, AHB-137 is advancing through a Phase 1b trial across multiple international locations and a concurrent Phase 2 trial, with a view towards a global solution for hepatitis B treatment.
About AusperBio and Its Mission
AusperBio is dedicated to transforming the landscape of biomedical technologies, focusing on oligonucleotide therapies and their associated delivery mechanisms. The company, with operations in the USA and other countries, strives to innovate in the realm of chronic illness treatment.
With the Med-Oligo™ ASO platform, AusperBio is not only refining ASO therapeutic designs but also enabling targeted delivery systems that significantly enhance treatment capabilities, making them more effective against a variety of conditions. Their commitment centers on combatting chronic hepatitis B, which remains a critical health challenge worldwide.
Frequently Asked Questions
What is AHB-137?
AHB-137 is an antisense oligonucleotide therapeutic designed to treat chronic hepatitis B, aiming for a functional cure.
When will the AHB-137 presentation take place?
The presentation is scheduled for November 18, 2024, at the Liver Meeting hosted by AASLD.
What are the expected outcomes of the presentation?
The presentation will discuss clinical trial results, including data showcasing HBsAg loss and seroconversion among participants.
What is AusperBio's focus?
AusperBio aims to advance oligonucleotide therapies, particularly for chronic hepatitis B, through innovative research and technology.
Where can I find more information about AusperBio?
For additional information about the company and its projects, please visit the AusperBio website.
About Investors Hangout
Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/
Disclaimer: The content of this article is solely for general informational purposes only; it does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice; the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. The author's interpretation of publicly available data shapes the opinions presented here; as a result, they should not be taken as advice to purchase, sell, or hold any securities mentioned or any other investments. The author does not guarantee the accuracy, completeness, or timeliness of any material, providing it "as is." Information and market conditions may change; past performance is not indicative of future outcomes. If any of the material offered here is inaccurate, please contact us for corrections.
Related Articles
- Kyocera Document Solutions Partners with ANREALAGE at Fashion Week
- Mayfair Gold Corp. Completes $6 Million Private Share Offering
- Huawei Introduces Innovative Solutions to Empower SMEs
- Nurses at Brigham and Women's Faulkner Secure New Contract
- Investors Urged to Join Customers Bancorp Class Action Today
- Legal Investigation into Securities Violations Affecting Shareholders
- Visa Inc. Faces Investigation Over Alleged Misleading Practices
- Tesla Faces Regulatory Hurdles for Full Self-Driving in China
- Investigation Alert for Xiao-I Corporation: Key Updates for Investors
- Understanding the Importance of Legal Counsel for Webtoon Investors
Recent Articles
- Class Action Filed Against Bumble, Inc. for Securities Fraud
- Empowering Future Doctors Through Dedicated Scholarship Program
- Empowering Tomorrow's Leaders: Benjamin Wey's Scholarship Impact
- Balance Point Capital Expands Investment and Compliance Teams
- AMMO, Inc. Faces Class Action Amid Financial Concerns
- Teamsters Local 284 Demands Fair Contract with Sutphen Corp
- Selena Gomez and Stars Unite for Rare Impact Fund Benefit Night
- Amscot's Ian MacKechnie Steps Up with $1M for Disaster Relief
- Charter Next Generation Promotes Sustainability in New Report
- Understanding Recent Developments for Paragon 28, Inc. - FNA
- Wix.com Stock Reaches 52-Week Peak Amid Growth Surge
- Primo Water Corporation Hits New High: Stock Rises Significantly
- Charming Shoppes Inc. Faces Challenges with Stock Prices
- Northwest Pipe Company Achieves Record 52-Week High Stock Growth
- GLU Stock Climbs to 52-Week High: What Investors Should Know
- Spirit AeroSystems Adjusts Executive Compensation for Boeing Merger
- ABVE Stock Drops to Record Low: What Investors Need to Know
- BofA Securities Confirms Neutral Stance on Lucid Group's Future
- Investors Anticipate Netflix's Earnings Amid Growth Trends
- Discover Bonchon's Exciting New Menu Selections Today
- Osisko Mining Shareholders Greenlight Acquisition by Gold Fields
- CX360, Inc. Welcomes FCC's Georouting Decision for Lifeline
- Kraken's Project Mercury: A New Era in Clean Energy Tech
- Exploring the $22.3 Billion Impact on Solar Funding in 2024
- Legal Action Highlights Concerns for Coinbase Global, Inc.
- Cboe CEO Insights: Market Dynamics and Robinhood's Impact
- New Fortress Energy Faces Class Action Lawsuit Over Securities Issues
- Rex Resources Corp. Accelerates Growth Amid Industry Resurgence
- Legal Action Emerges Against UPS for Alleged Securities Fraud
- Aviation Stocks Propel Industrial Sector Performance High
- Pomerantz Law Firm's Investigation into Humana Inc. Securities
- Legal Actions Surround WEBTOON Inc. After SEC Violations
- Understanding Biodexa Pharmaceuticals: Investigation Insights
- Shareholder Insights: Legal Action and Financial Challenges for ZoomInfo
- GitLab Inc. Faces Class Action Lawsuit Amid Financial Concerns
- Starbucks Faces Lawsuit After Unfavorable Financial Results
- Class Action Filed Against Super Micro Computer, Inc. - SMCI
- Adecco Launches Seasonal Hiring Drive for Holiday Employment
- IKO's New Color Shingle Line Elevates Your Rooftop Style
- Georgia Power Launches Flexible Payment Plans for Customers
- Quiddity Engineering Appoints Abdel Hamed as VP in Texas Office
- VyStar Credit Union Commemorates Global Unity in Finance
- Tompkins Financial Stock Surges to New Heights, Reveals Growth Potential
- Hyatt Hotels Adjusts Strategies Amid Analyst Downgrade
- WEC Energy Group Welcomes New Board Members for Growth
- NVIDIA Reaches New Heights Amidst AI Demand Surges
- GM Expands Its Reach for EV Mineral Investments
- Can Bitcoin Reach New All-Time Highs Again by Next Year?
- Michael Saylor's Strategic Insight: Bitcoin is Like Chess
- Jeremie Davinci's Bold Prediction for Meme Coins' Future